Johnson & Johnson JNJ:NYSE

RT Quote | Last NASDAQ LS, VOL From CTA | USD

After Hours: Last | 05/03/24 EDT

149.70

+0.43 (+0.29%)

Volume

392,405

149.27

-0.65 (-0.43%)

Volume

6,125,906

52 week range

143.13 - 175.97

Open149.89
Day High149.89
Day Low147.82
Prev Close149.92
52 Week High175.97
52 Week High Date08/10/23
52 Week Low143.13
52 Week Low Date04/18/24

Key Stats

Market Cap359.708B
Shares Out2.41B
10 Day Average Volume9.18M
Dividend4.96
Dividend Yield3.32%
Beta0.53
YTD % Change-4.77

KEY STATS

Open149.89
Day High149.89
Day Low147.82
Prev Close149.92
52 Week High175.97
52 Week High Date08/10/23
52 Week Low143.13
52 Week Low Date04/18/24
Market Cap359.708B
Shares Out2.41B
10 Day Average Volume9.18M
Dividend4.96
Dividend Yield3.32%
Beta0.53
YTD % Change-4.77

RATIOS/PROFITABILITY

EPS (TTM)6.69
P/E (TTM)22.32
Fwd P/E (NTM)14.13
EBITDA (TTM)31.292B
ROE (TTM)24.23%
Revenue (TTM)85.648B
Gross Margin (TTM)69.57%
Net Margin (TTM)19.93%
Debt To Equity (MRQ)48.03%

EVENTS

Earnings Date07/17/2024(est)
Ex Div Date05/20/2024
Div Amount1.24
Split Date-
Split Factor-

Latest On Johnson & Johnson

Cramer's thoughts on AMD, Johnson & Johnson, CVS Health, Super Micro and PinterestMay 1, 2024CNBC.com
Wednesday’s rapid fire: AMD, Johnson & Johnson, CVS Health, Super Micro and PinterestMay 1, 2024CNBC.com
Jim Cramer's top 10 things to watch in the stock market WednesdayMay 1, 2024CNBC.com
Johnson & Johnson will pay $6.5 billion to resolve nearly all talc ovarian cancer lawsuits in U.S.May 1, 2024CNBC.com
5 things to know before the stock market opens WednesdayMay 1, 2024CNBC.com

Content From Our Affiliates

New Prostate Cancer Treatment Data Not Much Help to Johnson & Johnson (NYSE:JNJ)22 Hours AgoTipRanks
Johnson & Johnson announces updated results from Cohort 2 of SunRISe-1 studyMay 3, 2024TipRanks
Cantor Fitzgerald healthcare/pharma analysts analyst/industry conference callMay 2, 2024TipRanks
Johnson & Johnson’s Strategic Settlement Plan for Ovarian Cancer Talc Claims: Financial Implications and OutlookMay 2, 2024TipRanks
Johnson & Johnson (NYSE:JNJ) Is Paying $6.5B to Settle LawsuitMay 1, 2024TipRanks

Profile

Johnson & Johnson, through its subsidiaries, is engaged in the research and development, manufacture, and sale of a range of products in the healthcare field. The Company’s primary focus is products related to human health and well-being. It operates through two segments: Innovative Medicine and MedTech. The Innovative Medicine segment is focused on various therapeutic areas, including immunology, infectious diseases, neuroscience, oncology, pulmonary hypertension, and...

Joaquin Duato

Chairman of the Board, Chief Executive Officer

Joseph Wolk

Chief Financial Officer, Executive Vice President

Tim Schmid

Executive Vice President, Worldwide Chairman of MedTech

Elizabeth Forminard

Executive Vice President, General Counsel

John Reed M.D., Ph.D.

Executive Vice President - Innovative Medicine, Research and Development

Address

One Johnson & Johnson Plaza

New Brunswick, NJ

08933

United States

https://www.jnj.com/

Top Peers

SYMBOL	LAST	CHG	%CHG
MRK Merck & Co Inc	127.51	-0.75	-0.58%
ABBV AbbVie Inc	163.79	+2.98	+1.85%
AZN AstraZeneca PLC	76.35	+0.55	+0.73%
RHHBY Roche Holding AG	29.83	+0.57	+1.95%
NVS Novartis AG	97.27	-0.07	-0.07%